DE60043870D1 - Auf bovinem Immundefizienvirus (BIV) basierende Vektoren - Google Patents

Auf bovinem Immundefizienvirus (BIV) basierende Vektoren

Info

Publication number
DE60043870D1
DE60043870D1 DE60043870T DE60043870T DE60043870D1 DE 60043870 D1 DE60043870 D1 DE 60043870D1 DE 60043870 T DE60043870 T DE 60043870T DE 60043870 T DE60043870 T DE 60043870T DE 60043870 D1 DE60043870 D1 DE 60043870D1
Authority
DE
Germany
Prior art keywords
biv
gene
vectors
operably linked
packaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043870T
Other languages
English (en)
Inventor
Tianci Luo
Robert David Berkowitz
Michael Kaleko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/734,836 external-priority patent/US6864085B2/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60043870D1 publication Critical patent/DE60043870D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60043870T 1999-12-14 2000-12-13 Auf bovinem Immundefizienvirus (BIV) basierende Vektoren Expired - Lifetime DE60043870D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46446099A 1999-12-14 1999-12-14
US24949200P 2000-11-17 2000-11-17
US09/734,836 US6864085B2 (en) 1999-12-14 2000-12-12 Bovine immunodeficiency virus (BIV) based vectors

Publications (1)

Publication Number Publication Date
DE60043870D1 true DE60043870D1 (de) 2010-04-01

Family

ID=27400217

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60033180T Expired - Lifetime DE60033180T2 (de) 1999-12-14 2000-12-13 Auf dem rinderimmunschwächevirus (biv) basierte vektoren
DE60043870T Expired - Lifetime DE60043870D1 (de) 1999-12-14 2000-12-13 Auf bovinem Immundefizienvirus (BIV) basierende Vektoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60033180T Expired - Lifetime DE60033180T2 (de) 1999-12-14 2000-12-13 Auf dem rinderimmunschwächevirus (biv) basierte vektoren

Country Status (10)

Country Link
EP (2) EP1852511B1 (de)
JP (3) JP2003517312A (de)
AT (2) ATE352636T1 (de)
AU (1) AU778110B2 (de)
CA (1) CA2392221C (de)
DE (2) DE60033180T2 (de)
ES (2) ES2340073T3 (de)
IL (2) IL149704A0 (de)
NZ (1) NZ519034A (de)
WO (1) WO2001044458A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
EP1852511B1 (de) * 1999-12-14 2010-02-17 Novartis AG Auf bovinem Immundefizienvirus (BIV) basierende Vektoren
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1373536B9 (de) 2001-03-13 2009-09-02 Novartis AG Lentivirale verpackungskonstrukte
CA2456169C (en) 2001-08-02 2012-05-22 Didier Trono Methods and compositions relating to improved lentiviral vector production systems
AU2002343458B2 (en) 2001-10-02 2008-03-20 Institut Clayton De La Recherche Methods and compositions relating to restricted expression lentiviral vectors and their applications
ES2208051B1 (es) * 2002-01-24 2005-08-16 Consejo Sup. Investig. Cientificas Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones.
CN1643164A (zh) * 2002-02-04 2005-07-20 诺瓦提斯公司 以重组牛免疫缺陷病毒为基础的基因转移系统
GB2450688A (en) * 2005-05-11 2009-01-07 Viragen Inc Ovalbumin promoter constructs for retroviral vectors
US10072067B2 (en) * 2014-01-30 2018-09-11 Children's Hospital Medical Center Fetal hemoglobin for genetic correction of sickle cell disease
GB202114532D0 (en) * 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380830A (en) * 1989-09-18 1995-01-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Molecular clones of bovine immunodeficiency-like virus
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
FR2768743B1 (fr) 1997-09-23 2001-09-14 Bio Merieux Procede de lyse de micro-organisme
AU747438B2 (en) * 1997-09-24 2002-05-16 Regents Of The University Of California, The Non-primate lentiviral vectors and packaging systems
ATE435297T1 (de) * 1998-05-22 2009-07-15 Oxford Biomedica Ltd Retrovirales verabreichungssystem
EP1852511B1 (de) * 1999-12-14 2010-02-17 Novartis AG Auf bovinem Immundefizienvirus (BIV) basierende Vektoren

Also Published As

Publication number Publication date
ATE352636T1 (de) 2007-02-15
EP1852511A1 (de) 2007-11-07
ES2281369T3 (es) 2007-10-01
CA2392221A1 (en) 2001-06-21
CA2392221C (en) 2012-01-31
JP2010166919A (ja) 2010-08-05
JP2003517312A (ja) 2003-05-27
ES2340073T3 (es) 2010-05-28
AU778110B2 (en) 2004-11-18
DE60033180T2 (de) 2007-10-25
DE60033180D1 (de) 2007-03-15
EP1238092A2 (de) 2002-09-11
EP1238092B1 (de) 2007-01-24
EP1852511B1 (de) 2010-02-17
WO2001044458A2 (en) 2001-06-21
JP2014110789A (ja) 2014-06-19
IL149704A0 (en) 2002-11-10
IL149704A (en) 2013-02-28
NZ519034A (en) 2005-02-25
AU2259801A (en) 2001-06-25
WO2001044458A3 (en) 2001-11-29
ATE458062T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
RU2733832C1 (ru) Искусственный ген Stbl_RBD_TrM_SC2, кодирующий бицистронную структуру, образованную последовательностями рецепторсвязывающего домена гликопротеина S коронавируса SARS-CoV-2, трансмембранного региона, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_TrM_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_TrM_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
Jeffers et al. Covalent modifications of the ebola virus glycoprotein
Garcia-Sastre et al. Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus
Pinter et al. Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes
Binley et al. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins
Hahn et al. Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation.
Richins et al. Sequence of figwort mosaic virus DNA (caulimovirus group)
ATE291632T1 (de) Auf lentivirus basierende gentransfer-vektoren
DE60043870D1 (de) Auf bovinem Immundefizienvirus (BIV) basierende Vektoren
DK1792997T3 (da) Lentiviral triplex DNA og vektorer og rekombinante celler indeholdende lentiviralt triplex DNA
Klewitz et al. Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity
JP2005502355A5 (de)
SG55158A1 (en) Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
Du et al. Efficient replication and generation of recombinant bovine adenovirus‐3 in nonbovine cotton rat lung cells expressing I‐SceI endonuclease
Schwartz et al. Distinct functions and requirements for the Cys-His boxes of the human immunodeficiency virus type 1 nucleocapsid protein during RNA encapsidation and replication
Bobkova et al. Identification of R-peptides in envelope proteins of C-type retroviruses
DE69631480D1 (de) Helfersystem zur wirkungssteigerung der aav-vektorproduktion
Beyer et al. Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: a single amino acid makes the difference
JP2004524805A5 (de)
Gaudin et al. Soluble ectodomain of rabies virus glycoprotein expressed in eukaryotic cells folds in a monomeric conformation that is antigenically distinct from the native state of the complete, membrane-anchored glycoprotein
Spannaus et al. The prototype foamy virus protease is active independently of the integrase domain
Kobayashi et al. Translation initiation of a bicistronic mRNA of Borna disease virus: a 16-kDa phosphoprotein is initiated at an internal start codon
Nakayama et al. Leucine at position 278 of the AIK-C measles virus vaccine strain fusion protein is responsible for reduced syncytium formation
RU2004116319A (ru) Система регулируемой экспрессии нуклеиновых кислот
Alkhatib et al. Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition